{"id":36473,"date":"2013-05-20T07:00:08","date_gmt":"2013-05-20T11:00:08","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=36473"},"modified":"2013-05-20T07:46:55","modified_gmt":"2013-05-20T11:46:55","slug":"beyond_unacceptable","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2013\/05\/20\/beyond_unacceptable\/","title":{"rendered":"beyond unacceptable…"},"content":{"rendered":"
In March, friend Nancy Wilson ran across an article syndicated in multiple small town papers hawking the antidepressant, Viibryd®, with commentary by Madhukar Trivedi – not labeled as an advertisement [the article…<\/a>, Viibryd® – coming to a hamlet near you…<\/a>]. Trivedi is at UT Southwestern where he heads their Depression Clinic. She wrote the chairman who responded that she had discussed it with Dr. Trivedi who denied any knowledge of how his name was associated with the article [read skepticism between the lines]. Now we are alerted<\/a> to a press release from Lundbeck about a new antidepressant, Vortioxetine<\/a> [Brintellix® or Rexulti®] submitted for approval [FDA, EMA]. Look who it quotes:
<\/strong><\/div>\n
\n
Vortioxetine clinical phase III data show significant improvement in symptoms of major depression<\/a>
NASDAQ OMX<\/em><\/font><\/strong>
May 18, 2013<\/div>\n

<\/p>\n

<\/p>\n
Vortioxetine clinical phase III data show significant improvement in symptoms of major depression<\/div>\n